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Synaptic vesicle protein 2A (SV2A) has been identified as
the binding site for the antiepileptic drug levetiracetam
and is thought to decrease neuronal excitability. Since
knockout of SV2A in mice leads to seizures, we hypoth-
esized that a reduction in SV2A expression promotes
seizure generation in epilepsy-associated brain tumors.
We compared the SV2A expression and distribution in
surgically removed tumor tissue (n 5 63) and peritu-
moral cortex (n 5 31) of patients with glial and
glioneuronal tumors to normal control cortex obtained
at autopsy in nonbrain tumor patients (n 5 6).
Additionally, we compared the SV2A expression and
distribution in tumor patients with epilepsy (n 5 39)
with SV2A expression in tumor patients without epi-
lepsy (n 5 24). Immunohistochemistry in control
cortex demonstrated strong and diffuse SV2A immunor-
eactivity (IR) throughout all cortical layers. Similar
strong SV2A IR (with the same diffuse distribution
pattern) was observed in the peritumoral cortical speci-
mens in both patients with and without epilepsy.
Modest SV2A IR was observed within the tumor area.
The SV2A-positive cells detected within the tumor area
were mainly entrapped neurons. Oligodendrogliomas
and glioneuronal tumors displayed variable SV2A neu-
ropil staining. In ganglioglioma (GG), strong SV2A IR
was present along the dysplastic neuronal cell borders
and processes. In both GG and dysembryoplastic neu-
roepithelial tumors, SV2A IR was occasionally observed
within the neuronal perikarya. We found no differences
in SV2A expression in the peritumoral cortex between
the patients with and without epilepsy, which suggests
that the role of SV2A in epileptogenesis in patients
with glial tumors is questionable. The distinct pattern
of SV2A IR in glioneuronal tumors suggests a redistribu-
tion of SV2A.
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E
pilepsy is a frequent symptom in patients with
brain tumors. Particularly, low-grade gliomas
(eg, WHO grade II astrocytomas and oligodendro-
gliomas) and glioneuronal tumors (eg, ganglioglioma
[GG] and dysembryoplastic neuroepithelial tumors
[DNTs]) are common causes of focal epilepsy.1 The
clinical significance and impact of epilepsy on the
quality of life of patients with glial and glioneuronal
tumors is high, especially as patients with these tumors
are very often resistant to treatment with a broad
range of antiepileptic drugs (AEDs).1–4 Moreover,
patients with brain tumors tend to be more sensitive to
side-effects of AEDs than those without brain
tumors.5,6 Furthermore, AEDs often interact with the
therapeutic regimen of these patients, such as che-
motherapeutic agents.
Given that the clinical significance is high and a more
effective therapy is urgently needed, it is important to get
more insight into epileptogenesis in patients with glial
and glioneuronal tumors. However, the cellular mechan-
isms underlying the epileptogenicity of these tumors are
largely unknown. Several mechanisms are possibly
involved. Much attention has been paid to alterations
of the balance between excitation and inhibition in the
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cortex adjacent to the tumor.1,7 In the large majority of
brain tumors, including gliomas, the epileptiform
activity is thought not to arise in the tumor itself, but
in the peritumoral tissue.8,9 However, in patients with
glioneuronal tumors, the cellular composition and
neurochemical profile of the tumors themselves, contain-
ing both glial and neuronal cells, also appear to be rel-
evant for the generation and propagation of seizure
activity.3,10,11
Recently, synaptic vesicle protein 2A (SV2A) has been
identified as the binding site for the AED levetiracetam
(LEV) and its analogs brivaracetam and selectracetam,
suggesting that SV2A is involved in neuronal (hyper-)
excitability.12–16 LEV is a relatively new drug with rela-
tively little side-effects and without well-known pharma-
cokinetic interactions that most traditional AEDs have.
Several studies have found that LEV is both effective and
safe as a therapy for epilepsy in patients with brain
tumors.1,17,18
Given the effectiveness of LEV in patients with glial
and glioneuronal tumors, the underlying mechanism of
action of LEV could be a lead to elucidate the pathophy-
siology of seizures in this patient group. SV2A is a mem-
brane glycoprotein present in synaptic vesicles of
neurons and endocrine cells and is the most widely dis-
tributed isoform of a family of three related synaptic
vesicle proteins (SV2A, SV2B, and SV2C).19 The
functions of these SV2 proteins are not completely
understood, but experimental studies using SV2A
and/or SV2A/SV2B knockout mice suggest that
these proteins play a role as calcium regulators in neuro-
transmitter release and modulate synaptic net-
works.20,21 Knockout of the SV2A protein in mice
leads to abnormal neurotransmission and development
of severe seizures.20,22 Moreover, reduced gene and
protein expression of SV2A has recently been observed
in the hippocampus after status epilepticus (SE) in a rat
model of temporal lobe epilepsy.23,24 These observations
suggest that a reduction in SV2A expression or activity
may promote seizure generation, although such a
reduction might not necessarily influence the efficacy
of LEV. LEV binding enhances an SV2A function that
inhibits abnormal neuronal activity that is not automati-
cally related to SV2A quantity.25 The expression of
SV2A has not been previously studied in primary brain
tumors. Assessment of SV2A expression in brain
tumors and in the peritumoral cortex may contribute
to understanding the epileptogenesis in brain tumors.
We hypothesize that a reduction in SV2A expression in
the peritumoral cortex correlates with the epileptogen-
esis in brain tumors.
For this purpose, we compared the expression of
SV2A protein in tumor tissue and peritumoral
cortex of patients with glial and glioneuronal tumors
with the expression in control cortex and we evaluated
the difference between the expression of SV2A
in tumor patients with and without epilepsy. In
order to do this, we defined not only the SV2A
expression, but also the distribution of SV2A
expression in tumor tissue, peritumoral cortex, and
control cortex.
Materials and Methods
Subjects
We examined surgical specimens of 51 brain tumor
patients with a glial tumor (30 glioblastoma multiforme
[GBM], 5WHO grade III astrocytoma, 8WHO grade III
oligodendroglioma, 4WHO grade II astrocytoma, and 4
WHO grade II oligodendroglioma) and 12 patients with
glioneuronal tumors (6GGs and 6DNTs). In 31 patients,
a significant amount of peritumoral tissue (cortex or
white matter adjacent to the lesion that did not include
the visible microscopical infiltration zone or significant
reactive gliosis; range, 0.7–2.3 cm; mean, 12 cm) was
resected aswell.On exposure to the same seizure activity,
drugs, fixation time, and obviously the same age and
gender, this material represents a good disease-reference
tissue. In addition, normal-appearing control cortex/
white matter was obtained at autopsy from 6 adult
control patients without a history of seizures or other
neurological diseases. The causes of death of these 6
patients were: 1 sudden cardiac death, 2 bronchopneu-
monias, 2 acute myocardial infarctions in combination
with chronic heart disease, and 1 acute myocardial
infarction with bronchopneumonia. All autopsies were
performed within 12 hours after death. A chart review
was conducted of all patients. Epilepsy was defined as
the experience of one or more seizures, and data regard-
ing seizure frequency and seizure type were obtained
from patient histories. We collected additional data
including age, gender, tumor location, and use of AED.
Patient data and specimens were obtained from the data-
bases of the departments of Neuropathology of the
Academic Medical Center (University of Amsterdam;
UVA) in Amsterdam and the University Medical Center
in Utrecht (UMCU), both situated in the Netherlands.
Informed consent was obtained for the use of brain
tissue and for access to medical records for research
purposes. Tissue was obtained and used in a manner
compliant with the Declaration of Helsinki. Two neuro-
pathologists (E.A., W.G.M.S.) reviewed all cases inde-
pendently, and the diagnosis was confirmed according
to the revised WHO classification of tumors of the
central nervous system.26
Tissue Preparation
Tissue was fixed in 10% buffered formalin and
embedded in paraffin. Paraffin-embedded tissue was sec-
tioned at 6 mm, mounted on organosilane-coated slides
(SIGMA, St. Louis, MO) and used for immunohisto-
chemical staining as described below.
Antibodies
Antibodies specific for glial fibrillary acidic protein
(GFAP; polyclonal rabbit, DAKO, Glostrup, Denmark;
1:4000; monoclonal mouse; DAKO; 1:50), vimentin
(mouse clone V9; DAKO; 1:1000), neuronal nuclear
protein (NeuN; mouse clone MAB377; Chemicon,
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Temecula, California; 1:2000), and synaptophysin
(mouse clone Sy38; DAKO; 1:200; rabbit anti-
synaptophysin; DAKO; 1:200) were used in the routine
immunohistochemical analysis of glial and glioneuronal
tumors. For the detection of SV2A, we used the mouse
anti-SV2A (15E11; 1:50, Abcam, Cambridge, UK).
Immunohistochemistry
For single-label immunohistochemistry, paraffin-
embedded sections were deparaffinized, re-hydrated, and
incubated for 20minutes in 0.3%H2O2 diluted in metha-
nol to quench the endogenous peroxidase activity. Antigen
retrieval was performed by incubation for 10 minutes at
1218C in citrate buffer (0.01 M, pH 6.0), and sections
were washed with phosphate-buffered saline (PBS) and
incubated for 30 minutes in 10% normal goat serum
(Harlan Sera-Lab, Loughborough, UK). Sections were
incubated with the primary antibodies overnight at 48C.
Hereafter, sections were washed in PBS and we used the
ready-for-use Powervision peroxidase system
(Immunologic, Duiven, The Netherlands) and 3,30-
diaminobenzidine (Sigma) as chromogen. Sections were
counterstainedwithhaematoxylin, dehydrated, andcover-
slipped. Sections incubated without the primary antibody
were essentially blank.
For double-labeling studies, after incubation of SV2A
combined with GFAP or synaptophysin overnight at
48C, sections were incubated for 2 hours at room temp-
erature (RT) with Alexa Fluorw 568-conjugated anti-
rabbit IgG and Alexa Fluorw 488 anti-mouse IgG
(1:100, Molecular Probes, Leiden, The Netherlands).
Sections were then analyzed bymeans of a laser scanning
confocal microscope (Leica TCS Sp2, Wetzlar,
Germany) equipped with an argon-ion laser.
Evaluation of Immunostaining
Semiquantitative evaluation of immunoreactivity (IR)
was performed as previously reported,27,28 using an
Olympus microscope and examining in each section
high-power non-overlapping fields (of 0.0655 
0.0655 mm width; each corresponding to 4.290 mm2;
using a square grid inserted into the eyepiece). The stain-
ing intensity was evaluated using the intensity score: a
semiquantitative three-point scale where IR is defined
as: 0, absent; 1, weak; 2, moderate; 3, strong staining.
This score represents the predominant staining intensity
found in each group (tumor, peritumoral, and control)
as averaged from the selected fields and the different sec-
tions per group (as previously described).27,28 The evalu-
ation of the IR in tumor specimens was performed in the
center of the lesion, and the infiltration zone was
disregarded.
We also performedoptical density (OD)measurements
in peritumoral and control cortex as previously reported.7
Sections were digitized using an Olympus microscope
equipped with a DP-10 digital camera (Olympus,
Tokyo, Japan). Images from consecutive, nonoverlapping
fields (magnification, 10) were collected using image
acquisition and analysis software (Phase 3 Image System
integrated with Image Pro Plus; Media Cybernetics,
Silver Spring, Maryland). The absolute pixel staining
density and the background from fields lacking immuno-
reactive profiles was determined. A mean OD value for
peritumoral cortex was calculated, expressed as a ratio
(ODR) of themeanODof the background, and compared
with control brain tissue.
Western Blot Analysis
For immunoblot analysis, freshly frozen human histo-
logically normal cortex (n ¼ 3), WHO grade II astrocy-
tomas (n ¼ 3), GBM (n ¼ 3), and GG (n ¼ 3) samples
were homogenized in lysis buffer containing 10 mM
Tris (pH 8.0), 150 mM NaCl, 10% glycerol, 1%
NP-40, 0.4 mg/mL sodium orthovanadate, 5 mM
EDTA (pH8.0), 5 mMNaF, and protease inhibitor cock-
tail (Boehringer, Mannheim, Germany). Protein content
was determined using the bicinchoninic acid method.29
For electrophoresis, equal amounts of proteins (50 mg/
lane) were separated by sodium dodecylsulfate-
polyacrylamide gel electrophoresis (SDS-PAGE; 10%
acrylamide). Separated proteins were transferred to nitro-
cellulose paper by electroblotting for 1 hour and 30
minutes (BioRad, Transblot SD, Hercules, California).
After blocking for 1 hour in TBST (20 mM Tris,
150 mM NaCl, 1% Tween, pH 7.5)/5% nonfat dry
milk, blots were incubated overnight with mouse
anti-SV2A (15E11; 1:500) or mouse anti-b-actin (clone
AC-15, Sigma; 1:50 000), used as reference protein.
After several washes in TBST, the membranes were incu-
bated in TBST/5% nonfat dry milk, containing horse-
radish peroxidase (HRP)-labeled goat anti-mouse
(DAKO; 1:2500) for 1 hour at RT. After washes in
TBST, IR was visualized using Lumi–light PLUS western
blotting substrate (Roche Diagnostics, Mannheim,
Germany) and digitized using a Luminescent Image
Analyzer (LAS-3000, Fuji Film, Tokyo, Japan). The OD
of each sample was measured using Image (Scion
Corporation, release beta 3b, Frederick, Maryland) soft-
ware. For each sample, theODof the SV2Awas calculated
relative to the OD of b-actin.
Statistical Analysis
Statistical analysiswasperformedwith SPSS forWindows.
Datawere analyzedwith one-way analysis of variance and
Fisher’s post hoc test to assess the difference between
groups (tumor, peritumoral, and control). Correlations
between immunostaining and different clinical variables
were assessed with the Spearman’s rank correlation test.
P, .05 was defined as statistically significant.
Results
Case Material
The clinical features of the cases included in this study
are summarized in Table 1. The mean age of tumor
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Table 1. Clinical and histopathological features
A II (n5 4) A III (n5 5) GBM (n5 30) O II (n5 4) O III (n5 8) GG (n5 6) DNT (n5 6) Control (n5 6)
Male gender 2 (50) 2 (40) 23 (76.7) 3 (75) 5 (62.5) 3 (50) 3 (50) 3 (50)
Age, yearsa 38 (31–45) 40 (32–56) 57 (41–76) 40 (31–51) 46 (41–57) 35 (19–46) 31 (18–38) 50 (21–63)
Location
Frontal 2 (50) 1 (20) 9 (30) — 6 (75) — — 1 (17)
Parietal 2 (50) — 2 (7) 1 (25) — — — 1 (17)
Temporal — — 11 (37) 1 (25) — 6 (100) 6 (100) 3 (50)
Occipital — 1 (20) 1 (3) 1 (25) — — — 1 (17)
Thalamus — — 1 (3) — — — — —
Parieto-occipital — 2 (40) 1 (3) — — — — —
Temporo-parietal — 1 (20) — — — — — —
Fronto-temporal — — 1 (3) — — — — —
Fronto-parietal — — 4 (13) 1 (25) 2 (25) — — —
Peritumoral tissue 2 (50) 3 (60) 10 (33) 3 (75) 3 (38) 5 (83) 5 (83) —
Epilepsy 2 (50) 1 (25) 14 (47) 3 (75) 7 (88) 6 (100) 6 (100) —
Duration epilepsya 13.6 (4–24) mo 2 (2–2) mo 13.9 (0.5–120) mo 31.5 (1–108) mo 22.3 (1–70) mo 16.5 (3–25) y 15.6 (2–22) y —
AED use —
LEV monotherapy — — 1 — 1 — — —
Seizure free — — 0 — 1 — — —
LEV add-on 1 — 1 1 — 2 2 —
Seizure free 1 — 0 0 — 0 0 —
Other AED 1 1 12 2 6 4 4 —
Seizure free 1 1 5 2 3 0 0 —
All data in number of patients (percentages) or as indicated.
A II, astrocytoma WHO II; A III, astrocytoma WHO III; GBM, glioblastoma multiforme; O II, oligodendroglioma WHO II; O III, oligodendroglioma, WHO III; GG, ganglioglioma; DNT,
dysembryoplastic neuroepithelial tumor; AED, antiepileptic drug; LEV, levetiracetam.
aMean (range).
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patients was 46.1 (SEM, 1.6) years. The mean age of
control patients was 49.5 (SEM, 6.2) years. Of the 63
tumor patients, 39 patients had epilepsy. Of the 31
patients of whom peritumoral tissue was resected as
well, 23 patients had epilepsy. In glioneuronal tumors,
the predominant seizure type was complex partial sei-
zures with or without secondary generalization. All 12
patients had seizures despite maximal tolerated doses
Fig. 1. SV2A IR in control, peritumoral cortex, and glial tumors. (A) and (B) Histologically normal cortex (CTX) and peritumoral CTX showing
diffuse and strong neuropil SV2A IR. Inserts in (A) show colocalization of synaptophysin (red; a) with SV2A (green; b); c, merged image. (C)
and (D) SV2A IR in astrocytomas (astrocytomas WHO grade II and anaplastic astrocytomas, WHO grade III) showing low SV2A IR within the
tumor area, with occasional expression in few residual neurons in the infiltration zone of the lesion (arrows in C); insert in (C) shows
colocalization (yellow; merged image) of synaptophysin (red) with SV2A (green). (E) and (F) SV2A IR in GBM showing low SV2A IR
within the tumor area, with occasionally focal areas of immunostained tumor cells. Insert in (E), merged image, shows GFAP-positive
cells (red) without SV2A (green) IR. Insert in (F), merged image, shows occasional colocalization of SV2A (green) with GFAP (red) in a
tumor cell. (G) and (H) SV2A IR in oligodendrogliomas showing variable matrix IR for SV2A in two anaplastic oligodendroglioma (Oligo,
WHO grade III). Scale bar in (A). (A) and (B) 70 mm; (C) and (E) 80 mm; (F)–(H) 40 mm.
de Groot et al.: SV2A in brain tumors and peritumoral cortex
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of AEDs (carbamazepine, valproic acid, phenytoin,
oxcarbazepine, and in 4 patients [2 GG and 2 DNT]
LEV as add-on therapy). In glial tumors the predominant
seizure type was simple partial seizures with or without
secondary generalization. Of patients with glial tumors,
13 (48%) patients had seizures despite maximal toler-
ated AEDs (carbamazepine, valproic acid, phenytoin,
clonazepam, lamotrigine, and LEV).
SV2A IR in Human Control, Glial, and Glioneuronal
Tumors
Control Cortex and Peritumoral Cortex. In control
cortex, SV2A IR was present in all cortical layers with
a diffuse neuropil staining (Fig. 1A). The neuronal
somata were devoid of staining; however, perikaryal
punctate labeling was detected in pyramidal neurons.
SV2A was co-localized with the presynaptic marker
synaptophysin (inserts in Fig. 1A). The monoclonal
SV2A antibody stained a protein of approximately
90 kDa (Fig. 2A), which is similar to the molecular
weight of SV2A.12
Similar to the observations found in control cortex, a
diffuse SV2A IR was observed in all cortical layers in the
peritumoral cortex of all 31 cases in which peritumoral
cortex was obtained (Figs 1B and 3E). Accordingly, the
mean intensity score and ODR in the peritumoral
cortex were not significantly different from control
cortex (Table 2; P . .05). No significant differences in
SV2A IR existed between peritumoral specimens of
patients with and without epilepsy and no significant
correlations were found between SV2A IR and other
clinical variables such as age at surgery, age at seizure
onset, duration of epilepsy, and AED regimens.
Tumor Tissue. Regarding the 63 tumor specimens, the
following results were found. Modest SV2A IR was
observed within the tumor area of both glial and glio-
neuronal tumors. The mean intensity score showed no
significant differences between different tumor types
(Table 3; P . .05). There was little evidence of SV2A
expression in tumor cells of astrocytomas grade II,
grade III, and GBM (Fig. 1C–F). The SV2A-positive
cells detected in these glial tumors are mainly
entrapped neurons (Fig. 1C). Only occasionally
SV2A was observed in GFAP-positive tumor cells in
GBM (inserts in Fig. 1E and F). Oligodendrogliomas
showed a variable SV2A matrix IR with intermittently
SV2A IR in the neuropil (Fig. 1G and H).
Glioneuronal tumors displayed variable SV2A neuro-
pil staining (Fig. 3). In GG, strong SV2A IR was
present along the dysplastic neuronal cell borders
and processes (perisomatic synapses; Fig 3A–C).
This epiperikaryal IR colocalized with the character-
istic strong perineuronal synaptophysin staining was
observed in dysplastic neuronal cells of GG
(Fig. 3D). In both GG and DNT, cytoplasmic SV2A
IR was occasionally observed within the neuronal
component of the tumor (Fig. 3A–C and G).
On western blot analysis, homogenates from astrocy-
tomas, GBM, and GG cases displayed a less dense band
than that observed in control cortex (Fig. 2A and B).
Accordingly, the mean intensity scores of IR in the
tumors are lower than the intensity scores of IR in
control cortex (Tables 2 and 3). Hence, glial and glio-
neuronal tumors generally show little SV2A expression
within the tumor cells, except for the strong IR within
neuronal components of the tumors.
Correlation Between SV2A Expression
and Distribution and Epilepsy
With this uncovered information we compared the
expression and distribution of SV2A in tumor tissue of
the 39 tumor patients with epilepsy with that of the 24
tumor patients without epilepsy. In both glial and glio-
neuronal tumors, no differences in IR were observed
between the specimens of patients with epilepsy and
without epilepsy. Both the tumor cells of patients with
and without epilepsy showed modest IR. The peritu-
moral cortex did not show any differences between the
two groups in IR as well. In addition, the mean intensity
score and ODR in the peritumoral cortex of the 23
tumor patients with epilepsy were not significantly
different from peritumoral cortex of the 8 tumor patients
without epilepsy (Table 2).
Discussion
The histologically normal peritumoral cortex in 31 of
the 63 brain tumor patients did not show significant
differences in neuropil expression for SV2A compared
with cortical tissue of 6 controls, and we found no
Fig. 2. Expression of SV2A in glial and glioneuronal tumors (A).
Representative immunoblot of SV2A in total homogenates from 3
cortex (Ctx), 3 astrocytomas grade II (Astr), 3 glioblastoma
multiforme (GBM), and 3 ganglioglioma (GG). (B) Densitometric
analysis of Western blots. Values (Optical density (OD) units) are
mean+SEM of 3 control cortex (Ctx), 3 Astr II, 3 GBM, and 3
GG relative to the OD of b-actin; all tumor specimens exhibited
lower SV2A expression compared with control cortex. *P, .05.
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differences in neuropil expression for SV2A in tumor
patients with and without epilepsy.
In contrast to our results, reduced protein expression
for SV2A has been detected in rat hippocampus after SE,
as well as in specimens of hippocampal sclerosis in
patients.24 Reduced expression of SV2A has also been
observed within surgical neocortical specimens of
patients with focal malformations of cortical develop-
ment (ie, focal cortical dysplasia).30 According to these
studies, reduction in SV2A expression might have been
expected in the epileptogenic zone of the lesions of our
patient group, which is the peritumoral cortex in case
of glial tumors and the tumor itself in case of glioneuro-
nal tumors. The absence of such a reduction (also in
patients with low-grade tumors and long duration of epi-
leptic activity) suggests that different mechanisms of
regulation of SV2A expression play a role in specific
pathologies.
Fig. 3. SV2A IR in glioneuronal tumors GGs, gangliogliomas; DNT, dysembryoplastic neuroepithelial tumors. (A)–(D) SV2A IR in GG
showing variable matrix SV2A IR within the tumor area with strong SV2A IR along the dysplastic neuronal cell borders and processes
(arrows in [A]–[C]). SV2A IR is occasionally observed within the neuronal perikarya (arrows in [B] and [C]). (D) Coexpression of
synaptophysin (a, SYN; red) with SV2A (b; green) in a dysplastic neuronal cell (c, merged image). (E)–(G) SV2A IR in DNT showing low
SV2A IR within the tumor area ([E]–[F]), but diffuse and strong neuropil IR in the peritumoral cortex (Peritumoral CTX [E]). SV2A IR is
occasionally observed within the neuronal perikarya within the tumor (arrow in [G]); the surrounding oligodendrocyte-like cells are
negative. Scale bar: (A)–(C), (F) 40 mm; (D) and (G) 20 mm; (E) 286 mm.
Table 2. SV2A immunoreactivity in control and peritumoral
cortex
Control
(n5 6)
Peritumoral cortex P Value
With epilepsy
(n5 23)
Without
epilepsy
(n5 8)
Intensity
score
2.8+0.13 2.5+0.11 2.6+0.15 ..05
ODR 68.5+2.8 68.5+1.5 66.6+2.3 ..05
Values represent the mean+SEM of the number of samples
indicated in parentheses. ODR, relative optical density ratio of
SV2A-IR.
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Low SV2A expression was expected in astroglial and
oligodendroglial tumor cells, since SV2A is a neuronal
and neuroendocrine cell marker. Indeed, SV2A IR was
not observed at all in GFAP-positive tumor cells of low-
grade astrocytomas, and only occasionally in high-grade
astrocytomas, expression of neuronal antigens has pre-
viously been shown in high-grade astrocytomas.31
Oligodendrogliomas displayed variable SV2A IR in the
neuropil. Although expression of neuronal markers has
been reported in oligodendroglial tumors more often
than in their astrocytic counterparts,32,33 the SV2A
matrix IR in oligodendrogliomas most likely represents
the preexisting neuronal structures. The presence of a
true intracellular expression of SV2A in oligodendroglial
cells requires further investigation, considering the lack
of specific oligodendroglial markers and the coexpres-
sion of neuronal markers in these tumor cells.
Neuropil staining was also observed in glioneuronal
tumors (GG and DNT), but was clearly restricted to
the neuronal component of the lesions. The high SV2A
expression in dysplastic neurons within GG specimens
could be explained by the disturbance of normal synap-
tic connection or by a compensatory mechanism in areas
of hyperexcitability. Accordingly, SV2A protein has
been shown to be implicated in the control of exocytosis,
modulating synaptic networks.20–22 A similar pattern of
IR outlining the border of dysplastic cells has been
reported in GG for synaptophysin.34–36 Colocalization
of these two presynaptic vesicle proteins has been corro-
borated in our study.
Surprisingly, no reduction of SV2A expression was
observed in the peritumoral cortex of glial tumors of
patients with epilepsy when compared with specimens
of patients without epilepsy. Although the mechanisms
of SV2A function are far from completely understood,
reduction in SV2A expression appears to lead to abnor-
mal neurotransmission and development of seizures.20,22
Since no reduction in SV2A expression was found in
peritumoral tissue, the role of SV2A in epileptogenesis
in patients with glial tumors remains questionable.
Nevertheless, the high efficacy of LEV in tumor-
related epilepsy, combined with the fact that SV2A is
identified as the binding site for LEV, suggests that
SV2A contributes to the mechanism of seizure gener-
ation and maintenance in these patients. It is imaginable
that not the reduction of SV2A expression but the loss of
SV2A function initiates the loss of control of synaptic
vesicle exocytosis and consequently alters neurotrans-
mission and eventually contributes to the epileptogenesis
in patients with brain tumors. LEV might reduce exces-
sive neuronal activity by modulating SV2A function and
restoring the ability of a neuron to regulate its neuro-
transmitter release.25
The relationship between SV2A expression and the
efficacy of LEV is not clear either. No evidence exists
that a reduced expression of SV2A interferes with the
effectiveness of LEV (ie, in focal cortical dysplasia)30
and it is not known if a high expression of SV2A pro-
motes the efficacy of LEV. Additional prospective clini-
cal studies are required to further address this issue.
This study provides a large population of tumor
patients with and without epilepsy. However, the data
remain retrospective. Hence, it is interesting to investi-
gate the expression and cellular distribution of SV2A
in patients who were effectively treated with LEV and
who were ineffectively treated with LEV in a prospective
fashion.
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